Can-Fite BioPharma Ltd. (TLV:CANF)
1.000
0.00 (0.00%)
Nov 6, 2025, 2:07 PM IDT
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2024. The number of employees decreased by 3 or -37.50% compared to the previous year.
Employees
5
Change (1Y)
-3
Growth (1Y)
-37.50%
Revenue / Employee
377.36K ILS
Profits / Employee
-5.93M ILS
Market Cap
51.22M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 0 | - |
| Dec 31, 2020 | 8 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Teva Pharmaceutical Industries | 35,686 |
| Danel (Adir Yeoshua) | 4,290 |
| Novolog (Pharm-Up 1966) | 936 |
| Kamada | 420 |
| InterCure | 320 |
| Bait Bakfar | 227 |
| Ilex Medical | 178 |
| SofWave Medical | 126 |
Can-Fite BioPharma News
- 5 days ago - CANF: HC Wainwright Initiates Buy Rating with $2.50 Price Target | CANF Stock News - GuruFocus
- 7 weeks ago - CANF: Analyst Jason Kolbert Maintains Buy Rating and $11 PT | CANF Stock News - GuruFocus
- 7 weeks ago - Can-Fite BioPharma (CANF) Reports Breakthrough in Liver Cirrhosis Treatment - GuruFocus
- 2 months ago - Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.2M - Seeking Alpha
- 2 months ago - Can-Fite Reports H1 2025 Financial Results and Clinical Update - GlobeNewsWire
- 3 months ago - Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone - GlobeNewsWire
- 3 months ago - Can-Fite Announces Up To $15.0 Million Public Offering - GlobeNewsWire
- 3 months ago - Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia - GlobeNewsWire